Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

NCT01308580 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01308580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01308580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
August 31, 2015
Enrollment
1,200 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer